SINT Quote, Financials, Valuation and Earnings

NeuroOne Medical Technologies Corp. has a net margin of -1701.44% compared to SINTX Technologies, Inc.'s net margin of -88.5%. SINTX Technologies, Inc.'s return on equity of -208.36% beat NeuroOne Medical Technologies Corp.'s return on equity of -166.02%.

SINTX Technologies, Inc. has a consensus price target of $16.75, signalling upside risk potential of 336.2%. On the other hand NeuroOne Medical Technologies Corp. has an analysts' consensus of $2.23 which suggests that it could grow by 231.6%. Given that SINTX Technologies, Inc. has higher upside potential than NeuroOne Medical Technologies Corp., analysts believe SINTX Technologies, Inc. is more attractive than NeuroOne Medical Technologies Corp..

SINTX Technologies, Inc. has a beta of 0.633, which suggesting that the stock is 36.717% less volatile than S&P 500. In comparison NeuroOne Medical Technologies Corp. has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.673%.

SINTX Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies, Inc. pays -- of its earnings as a dividend. NeuroOne Medical Technologies Corp. pays out -- of its earnings as a dividend.

SINTX Technologies, Inc. quarterly revenues are $208K, which are smaller than NeuroOne Medical Technologies Corp. quarterly revenues of $1.7M. SINTX Technologies, Inc.'s net income of -$3.5M is lower than NeuroOne Medical Technologies Corp.'s net income of -$1.5M. Notably, SINTX Technologies, Inc.'s price-to-earnings ratio is -- while NeuroOne Medical Technologies Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies, Inc. is 6.51x versus 2.45x for NeuroOne Medical Technologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband, Inc. has a net margin of -1701.44% compared to SINTX Technologies, Inc.'s net margin of -321.33%. SINTX Technologies, Inc.'s return on equity of -208.36% beat Nutriband, Inc.'s return on equity of -117.44%.

SINTX Technologies, Inc. has a consensus price target of $16.75, signalling upside risk potential of 336.2%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 196.44%. Given that SINTX Technologies, Inc. has higher upside potential than Nutriband, Inc., analysts believe SINTX Technologies, Inc. is more attractive than Nutriband, Inc..

SINTX Technologies, Inc. has a beta of 0.633, which suggesting that the stock is 36.717% less volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.907, suggesting its more volatile than the S&P 500 by 90.735%.

SINTX Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies, Inc. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.

SINTX Technologies, Inc. quarterly revenues are $208K, which are smaller than Nutriband, Inc. quarterly revenues of $622.5K. SINTX Technologies, Inc.'s net income of -$3.5M is lower than Nutriband, Inc.'s net income of -$2M. Notably, SINTX Technologies, Inc.'s price-to-earnings ratio is -- while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies, Inc. is 6.51x versus 21.85x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

enVVeno Medical Corp. has a net margin of -1701.44% compared to SINTX Technologies, Inc.'s net margin of --. SINTX Technologies, Inc.'s return on equity of -208.36% beat enVVeno Medical Corp.'s return on equity of -57.7%.

SINTX Technologies, Inc. has a consensus price target of $16.75, signalling upside risk potential of 336.2%. On the other hand enVVeno Medical Corp. has an analysts' consensus of $12.50 which suggests that it could grow by 3121.65%. Given that enVVeno Medical Corp. has higher upside potential than SINTX Technologies, Inc., analysts believe enVVeno Medical Corp. is more attractive than SINTX Technologies, Inc..

SINTX Technologies, Inc. has a beta of 0.633, which suggesting that the stock is 36.717% less volatile than S&P 500. In comparison enVVeno Medical Corp. has a beta of 1.063, suggesting its more volatile than the S&P 500 by 6.264%.

SINTX Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies, Inc. pays -- of its earnings as a dividend. enVVeno Medical Corp. pays out -- of its earnings as a dividend.

SINTX Technologies, Inc. quarterly revenues are $208K, which are larger than enVVeno Medical Corp. quarterly revenues of --. SINTX Technologies, Inc.'s net income of -$3.5M is higher than enVVeno Medical Corp.'s net income of -$4.5M. Notably, SINTX Technologies, Inc.'s price-to-earnings ratio is -- while enVVeno Medical Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies, Inc. is 6.51x versus 473.07x for enVVeno Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of -1701.44% compared to SINTX Technologies, Inc.'s net margin of 7.29%. SINTX Technologies, Inc.'s return on equity of -208.36% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

SINTX Technologies, Inc. has a consensus price target of $16.75, signalling upside risk potential of 336.2%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that SINTX Technologies, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe SINTX Technologies, Inc. is more attractive than Phibro Animal Health Corp..

SINTX Technologies, Inc. has a beta of 0.633, which suggesting that the stock is 36.717% less volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

SINTX Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. SINTX Technologies, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

SINTX Technologies, Inc. quarterly revenues are $208K, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. SINTX Technologies, Inc.'s net income of -$3.5M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, SINTX Technologies, Inc.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies, Inc. is 6.51x versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.